DIRA, DITRA, and new insights into pathways of skin inflammation: What's in a name?

Archives of Dermatology

Volumn 148, Issue 3, 2012, Pages 381-384

  Cowen, Edward W ^a   Goldbach Mansky, Raphaela ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; INTERLEUKIN 1BETA; INTERLEUKIN 36; INTERLEUKIN 6; UNCLASSIFIED DRUG;

DEFICIENCY OF THE INTERLEUKIN 1 RECEPTOR ANTAGONIST; DEFICIENCY OF THE INTERLEUKIN 36 RECEPTOR ANTAGONIST; EDITORIAL; GENE DELETION; HUMAN; IL 36RN GENE; MOLECULAR PATHOLOGY; MONOGENIC DISORDER; MUTATOR GENE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PUSTULAR PSORIASIS; SKIN INFLAMMATION;

ANTIRHEUMATIC AGENTS; CHROMOSOME ABERRATIONS; CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 2; GENES, RECESSIVE; HEREDITARY AUTOINFLAMMATORY DISEASES; HUMANS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; MALE; PSORIASIS;

EID: 84858714125     PISSN: 0003987X     EISSN: 15383652     Source Type: Journal    
DOI: 10.1001/archdermatol.2011.3014     Document Type: Editorial

References (25)

1. Brau-Javier CN, Gonzales-Chavez J, Toro JR. Chronic cutaneous pustulosis due to a 175-kb deletion on chromosome 2q13: excellent response to anakinra. Arch Dermatol. 2012;148(3):301-304.
2. Aksentijevich I, Masters SL, Ferguson PJ, et al. An autoinflammatory disease with deficiency of the interleukin-1-receptor antagonist. N Engl J Med. 2009;360 (23):2426-2437.
3. Goldbach-Mansky R, Kastner DL. Autoinflammation: the prominent role of IL-1 in monogenic autoinflammatory diseases and implications for common illnesses. J Allergy Clin Immunol. 2009;124(6):1141-1149.
4. Goldbach-Mansky R. Current status of understanding the pathogenesis and management of patients with NOMID/CINCA. Curr Rheumatol Rep. 2011;13(2): 123-131.
5. Marrakchi S, Guigue P, Renshaw BR, et al. Interleukin-36-receptor antagonist deficiency and generalized pustular psoriasis. N Engl J Med. 2011;365(7):620- 628.
6. Onoufriadis A, Simpson MA, Pink AE, et al. Mutations in IL36RN/IL1F5 are associated with the severe episodic inflammatory skin disease known as generalized pustular psoriasis. Am J Hum Genet. 2011;89(3):432-437.
7. Debets R, Timans JC, Homey B, et al. Two novel IL-1 family members, IL-1 delta and IL-1 epsilon, function as an antagonist and agonist of NF-kappa B activation through the orphan IL-1 receptor-related protein 2. J Immunol. 2001;167(3): 1440-1446. (Pubitemid 32703142)
8. Towne JE, Garka KE, Renshaw BR, Virca GD, Sims JE. Interleukin (IL)-1F6, IL-1F8, and IL-1F9 signal through IL-1Rrp2 and IL-1RAcP to activate the pathway leading to NF-kappaB and MAPKs. J Biol Chem. 2004;279(14):13677-13688. (Pubitemid 38468896)
9. Jesus AA, Osman M, Silva CA, et al. A novel mutation of IL1RN in the deficiency of interleukin-1 receptor antagonist syndrome: description of two unrelated cases from Brazil. Arthritis Rheum. 2011;63(12):4007-4017.
10. Reddy S, Jia S, Geoffrey R, et al. An autoinflammatory disease due to homozygous deletion of the IL1RN locus. N Engl J Med. 2009;360(23):2438-2444.
11. Dinarello CA. Biologic basis for interleukin-1 in disease. Blood. 1996;87(6):2095- 2147.
12. Kumar S, McDonnell PC, Lehr R, et al. Identification and initial characterization of four novel members of the interleukin-1 family. J Biol Chem. 2000;275(14): 10308-10314. (Pubitemid 30202089)
13. Smith DE, Renshaw BR, Ketchem RR, Kubin M, Garka KE, Sims JE. Four new members expand the interleukin-1 superfamily. J Biol Chem. 2000;275(2): 1169-1175. (Pubitemid 30051168)
14. Blumberg H, Dinh H, Trueblood ES, et al. Opposing activities of two novel members of the IL-1 ligand family regulate skin inflammation. J Exp Med. 2007; 204(11):2603-2614. (Pubitemid 350044786)
15. Blumberg H, Dinh H, Dean C Jr, et al. IL-1RL2 and its ligands contribute to the cytokine network in psoriasis. J Immunol. 2010;185(7):4354-4362.
16. Zaba LC, Fuentes-Duculan J, Eungdamrong NJ, et al. Psoriasis is characterizedby accumulation of immunostimulatory and Th1/Th17 cell-polarizing myeloid dendritic cells. J Invest Dermatol. 2009;129(1):79-88.
17. Nestle FO, Di Meglio P, Qin JZ, Nickoloff BJ. Skin immune sentinels in health and disease. Nat Rev Immunol. 2009;9(10):679-691.
18. Bigler CF, Norris DA, Weston WL, Arend WP. Interleukin-1 receptor antagonist production by human keratinocytes. J Invest Dermatol. 1992;98(1):38-44.
19. Johnston A, Xing X, Guzman AM, et al. IL-1F5, -F6, -F8, and -F9: a novel IL-1 family signaling system that is active in psoriasis and promotes keratinocyte antimicrobial peptide expression. J Immunol. 2011;186(4):2613-2622.
20. Lutz V, Lipsker D. Acitretin- and tumor necrosis factor inhibitor-resistant acrodermatitis continua of Hallopeau responsive to the interleukin 1 receptor antagonist anakinra. Arch Dermatol. 2012;148(3):297-299.
21. Viguier M, Guigue P, Pagès C, Smahi A, Bachelez H. Successful treatment of generalized pustular psoriasis with the interleukin-1-receptor antagonist Anakinra: lack of correlation with IL1RN mutations. Ann Intern Med. 2010;153(1): 66-67.
22. Kluger N, Gil-Bistes D, Guillot B, Bessis D. Efficacy of anti-interleukin-1 receptor antagonist anakinra (Kineret) in a case of refractory Sweet's syndrome. Dermatology. 2011;222(2):123-127.
23. Kieffer C, Cribier B, Lipsker D. Neutrophilic urticarial dermatosis: a variant of neutrophilic urticaria strongly associated with systemic disease: report of 9 new cases and review of the literature. Medicine (Baltimore). 2009;88(1):23-31.
24. Lipsker D, Perrigouard C, Foubert A, Cribier B. Anakinra for difficult-to-treat neutrophilic panniculitis: IL-1 blockade as a promising treatment option for neutrophilmediated inflammatory skin disease. Dermatology. 2010;220(3):264-267.
25. Jung N, Hellmann M, Hoheisel R, et al. An open-label pilot study of the efficacy and safety of anakinra in patients with psoriatic arthritis refractory to or intolerant of methotrexate (MTX). Clin Rheumatol. 2010;29(10):1169-1173.